Trial Profile

A Phase 2, Open-Label, Multi-center Study of AL101 in Patients With Adenoid Cystic Carcinoma (ACC) Bearing Activating Notch Mutations

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 05 Feb 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Osugacestat (Primary)
Indications Adenoid cystic carcinoma
Focus Therapeutic Use
Acronyms ACCURACY
Sponsors Ayala Pharmaceuticals

Most Recent Events

11 Dec 2023 Status changed from active, no longer recruiting to completed.
24 Oct 2023 Final results from this trial and a meta-analysis of clinical outcomes with other clinical trials presented at the 48th European Society for Medical Oncology Congress
01 Aug 2023 According to an Ayala Pharmaceuticals media release, data from this trial will be presented at the European Society for Molecular Oncology (ESMO) Congress 2023.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com